Wavy Abstract Background

Potential Use of Cellular Stromal Vascular Fraction in Post-COVID-19 Injury and Respiratory Distress

June 2nd, 2020


SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial to treat post-COVID 19 survivors with AD cSVF.


Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.


This article was published in the Journal of Current Medical Research and Opinion.

Potential Use of Cellular Stromal Fraction in Post-COVID-19 Injury and Respiratory Distres
.
Download • 716KB
 

Want to learn more from Dr. Alexander?

Visit the SDARTs Online Learning Center >

Recent Posts

See All

June 16th, 2020 SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial to treat post-COVID 19 survivors with AD cSVF. Many moderate to se